CHICAGO--(BUSINESS WIRE)--GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the launch of a secondary underwritten public offering (the “Offering”) of 10,000,000 shares of its common stock (the “GEHC Shares”). GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below)..

芝加哥--（商业新闻短讯）--通用电气医疗保健技术公司（纳斯达克股票代码：GEHC）（以下简称“公司”或“通用电气医疗保健”）今天宣布，将启动其10000000股普通股（以下简称“GEHC股”）的二次承销公开发行（以下简称“发行”）。GE HealthCare没有出售任何普通股，也不会从发售中出售GEHC股份或从债转股（如下所述）中获得任何收益。。

Prior to the closing of the Offering, GE Aerospace (General Electric Company) is expected to exchange the GEHC Shares for indebtedness of GE Aerospace held by Morgan Stanley Bank, N.A. and Morgan Stanley Senior Funding, Inc. (together, the “MS Lenders”), affiliates of Morgan Stanley & Co. LLC, the selling stockholder in the Offering by designation of the MS Lenders.

在本次发行结束之前，GE航空航天（通用电气公司）预计将用GEHC股份交换由摩根士丹利银行（Morgan Stanley Bank，N.A.）和摩根士丹利高级融资公司（Morgan Stanley Senior Funding，Inc.）持有的GE航空航天的债务（统称为“MS贷款人”），摩根士丹利有限责任公司（Morgan Stanley&Co.LLC）的附属公司，是本次发行中指定的出售股东。

Following the debt-for-equity exchange, if consummated, Morgan Stanley & Co. LLC, as the selling stockholder in the Offering, intends to sell the GEHC Shares to the underwriters in the Offering. The selling stockholder in the Offering has granted the underwriters an option to purchase 1,500,000 additional shares of GE HealthCare common stock for settlement on or before September 30, 2024..

债转股交易完成后，摩根士丹利股份有限公司（Morgan Stanley&Co.LLC）作为本次发行的售股股东，打算将GEHC股份出售给本次发行的承销商。本次发行的售股股东已授予承销商购买1500000股GE HealthCare普通股的期权，以在2024年9月30日或之前进行结算。。

Morgan Stanley and Citigroup are acting as the lead joint book-running managers for the Offering.

摩根士丹利（MorganStanley）和花旗集团（Citigroup）担任此次发行的主要联合账簿管理人。

The Company has filed an automatically effective shelf registration statement (including a prospectus) on Form S-3 with the U.S. Securities and Exchange Commission (the “SEC”) for the Offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the Company has filed with the SEC for more complete information about the Company and this Offering.

公司已向美国证券交易委员会（“SEC”）提交了一份表格S-3中的自动生效货架登记声明（包括招股说明书），用于本通信相关的发行。在投资之前，您应该阅读注册声明中的招股说明书以及公司向SEC提交的其他文件，以获得有关公司和本次发行的更完整信息。

The Offering will be made only by means of a free writing prospectus, the prospectus and the accompanying prospectus supplement relating to the Offering. You may obtain these documents for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, copies of the free writing prospectus, the prospectus and, when available, the accompanying prospectus supplement relating to the Offering may be obtained from Morgan Stanley & Co.

本次发行将仅通过免费书面招股说明书、招股说明书和随附的与本次发行有关的招股说明书补充资料进行。您可以通过访问美国证券交易委员会网站www.SEC.gov上的EDGAR免费获取这些文件。或者，可以从摩根士丹利公司获得与本次发行有关的免费书面招股说明书、招股说明书和随附的招股说明书补充资料（如果有）。

LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; and Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Tel: 800-831-9146)..

有限责任公司，收件人：招股说明书部，180 Varick Street，2nd Floor，New York，NY 10014；和花旗集团，转交纽约州埃奇伍德长岛大道1155号Broadridge Financial Solutions，邮编11717（电话：800-831-9146）。。

This press release shall not constitute an offer to sell or the solicitation of any offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不构成出售要约或招揽任何购买要约，也不构成在根据任何州或司法管辖区的证券法律注册或资格之前，在任何州或司法管辖区出售这些证券是非法的。。

About GE HealthCare Technologies Inc.

关于GE HealthCare Technologies Inc。

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier.

GE HealthCare是全球领先的医疗技术、药物诊断和数字解决方案创新者，致力于提供集成的解决方案、服务和数据分析，使医院更高效、临床医生更有效、治疗更精确，患者更健康、更快乐。

Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring.

GE HealthCare为患者和提供者服务了125多年，正在推进个性化、互联化和富有同情心的护理，同时简化患者跨越护理路径的旅程。我们的成像、超声波、患者护理解决方案和药物诊断业务共同帮助改善患者护理，从诊断到治疗再到监测。

We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits..

我们是一家价值196亿美元的企业，拥有约51000名员工，致力于创造一个医疗保健无限的世界。。

Forward‐Looking Statements

前瞻性声明

This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the size, timing or results of the Offering and the selling stockholders’ intent to offer shares of common stock, and reflect management’s current plans, estimates and expectations and are inherently uncertain.

本版本包含前瞻性声明。这些前瞻性陈述可以通过单词和单词的变体来识别，例如“将”、“期望”、“可能”、“将”、“可能”、“计划”和类似的表达。这些前瞻性陈述可能包括但不限于关于发行规模、时间或结果以及献售股东发行普通股的意图的陈述，反映了管理层当前的计划、估计和预期，并且具有内在的不确定性。

The inclusion of any forward-looking information in this release should not be regarded as a representation that the future plans, estimates or expectations contemplated will be achieved. These forward-looking statements involve risks and uncertainties, many of which are beyond the Company’s control.

本版本中包含的任何前瞻性信息不应被视为表示将实现预期的未来计划、估计或预期。。

Factors that could cause actual results to differ materially from those described in the Company’s forward-looking statements include, but are not limited to, operating in highly competitive markets; our ability to control increases in healthcare costs and any subsequent effect on demand for the Company’s products, services, or solutions; the Company’s ability to operate effectively as an independent, publicly-traded company; and the other factors detailed in the Company’s Registration Statement on Form S-3 filed on February 15, 2024, as well as other risks discussed in the Company’s filings with the U.S.

可能导致实际结果与公司前瞻性声明中描述的结果存在重大差异的因素包括但不限于在高度竞争的市场中运营；我们能够控制医疗保健成本的增加以及对公司产品、服务或解决方案需求的任何后续影响；；以及该公司于2024年2月15日提交的s-3表格登记声明中详述的其他因素，以及该公司向美国提交的文件中讨论的其他风险。

Securities and Exchange Commission. Please also see the “Risk Factors” section of the Company’s Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actu.

证券交易委员会。另请参阅公司向美国证券交易委员会提交的表格10-K中的“风险因素”部分，以及其在未来提交的文件中所做的任何更新或修订。公司目前不知道或目前认为不重要的其他因素可能会导致公司的actu。